跳转至内容
Merck
CN
  • Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.

Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.

Acta pharmacologica Sinica (2014-09-16)
Qiu-yu Xu, Yin-hui Liu, Qi Zhang, Bo Ma, Zhen-dong Yang, Lei Liu, Di Yao, Guang-bo Cui, Jing-jing Sun, Zi-mei Wu
摘要

To investigate the metabolite changes caused by simvastatin or fenofibrate intervention in diet-induced hyperlipidemia rats using a GC-MS-based metabolomic profiling approach. SD rats were fed with high-lipid diet for 4 weeks to induce hyperlipidemia, then the rats were fed with normal diet, and orally administered with simvastatin (10 mg·kg(-1)·d(-1)) or fenofibrate (150 mg·kg(-1)·d(-1)) for 2 weeks. Blood samples were collected once a week, and potential biomarkers were examined using commercial assay kits and a metabolomic approach. The metabolomics data were analyzed using a multivariate statistical technique and a principal component analysis (PCA). Oral administration of simvastatin or fenofibrate significantly decreased the plasma levels of total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol and increased the plasma level of high-density lipoprotein (HDL) cholesterol in the hyperlipidemia rats. Plasma samples were scattered in the PCA scores plots in response to the diet and to the drugs administered. The main metabolites changed in the hyperlipidemia rats were cholesterol, creatinine, linoleic acid, β-hydroxybutyric acid, tyrosine, isoleucine and ornithine. The plasma level of creatinine was significantly lower in the simvastatin-treated rats than in the fenofibrate-treated rats. The plasma tyrosine concentration was declined following intake of high-lipid diet, which was reversed by fenobrate, but not by simvastatin. A series of potential biomarkers including tyrosine, creatinine, linoleic acid, β-hydroxybutyric acid and ornithine have been identified by metabolomic profiling, which may be used to identify the metabolic changes during hyperlipidemia progression.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
庚烷, suitable for HPLC, ≥99%
Sigma-Aldrich
庚烷, ReagentPlus®, 99%
Supelco
N-甲基-N-(三甲基硅烷基)三氟乙酰胺, derivatization grade (GC derivatization), LiChropur, ≥98.5%
Sigma-Aldrich
三甲基氯硅烷, ≥98.0% (GC)
Sigma-Aldrich
庚烷, HPLC Plus, for HPLC, GC, and residue analysis, 99%
Sigma-Aldrich
庚烷, puriss. p.a., reag. Ph. Eur., ≥99% n-heptane basis (GC)
Sigma-Aldrich
乙酸酐, ReagentPlus®, ≥99%
Supelco
N-甲基-N-(三甲基硅烷基)三氟乙酰胺, synthesis grade
Sigma-Aldrich
乙酸酐, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99% (GC)
Sigma-Aldrich
三甲基氯硅烷, purified by redistillation, ≥99%
Sigma-Aldrich
乙酸酐, ACS reagent, ≥98.0%
Sigma-Aldrich
庚烷, anhydrous, 99%
Supelco
N-甲基-N-(三甲基硅烷基)三氟乙酰胺, BioReagent, for silylations, LiChropur
Sigma-Aldrich
三甲基氯硅烷, puriss., ≥99.0% (GC)
Supelco
N -甲基-双(三氟乙酰胺), derivatization grade (GC derivatization), LiChropur, ≥97.0% (GC)
Sigma-Aldrich
庚烷, suitable for HPLC, ≥96%
Supelco
含有1%三甲基氯硅烷的N-甲基-N-(三甲基甲硅烷基)三氟乙酰胺, derivatization grade (GC derivatization), LiChropur
Supelco
庚烷, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
庚烷, analytical standard
Supelco
三甲基氯硅烷, derivatization grade (GC derivatization), LiChropur, ≥99.0% (GC)
Supelco
乙酸酐, derivatization grade (GC derivatization), LiChropur, ≥99.0%
Sigma-Aldrich
三甲基氯硅烷, Wacker Chemie AG, ≥99.0% (GC)
Supelco
N -甲基-双(三氟乙酰胺), derivatization grade (GC derivatization), LiChropur, ≥99.0% (GC)
Sigma-Aldrich
三甲基氯硅烷 溶液, 1.0 M in THF
Sigma-Aldrich
庚烷, biotech. grade, ≥99%